Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yuxin Mu
Observed names:
Mu, Yuxin,
Y X Mu,
Y. Mu
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Shanghai Medical College of Fudan University,
Chinese Academy of Medical Sciences & Peking Union Medical College,
Fudan University,
Fudan University Shanghai Cancer Center,
Cancer Hospital of Chinese Academy of Medical Sciences
ORCID:
0000-0002-8465-6933
Observed ORCID:
0000-0002-8465-6933
OpenAlex ID:
A5012563966
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
2020
·
Yuxin Mu
, Xuezhi Hao
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
71
PDF
Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib
2019
·
Yuxin Mu
, Xuezhi Hao
, et al.
·
Targeted Oncology
·
42
PDF
Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer
2020
·
Yuxin Mu
, Ke Yang
, et al.
·
Frontiers in Oncology
·
37
PDF
Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer
2008
·
W. L. Akerley
, C. J. Langer
, et al.
·
Journal of Clinical Oncology
·
33
Disease monitoring of epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA
2022
·
Yan Li
, Ziyi Xu
, et al.
·
Thoracic Cancer
·
30
Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study
2019
·
Hongge Liang
, Xia Song
, et al.
·
Thoracic Cancer
·
28
PDF
Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis
2019
·
P. Xing
, Y. Mu
, et al.
·
Clinical & Translational Oncology
·
24
PDF
Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study
2019
·
Yuxin Mu
, Puyuan Xing
, et al.
·
Cancer Management and Research
·
21
PDF
Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
2021
·
Jiani Wang
, Qingyuan Zhang
, et al.
·
Targeted Oncology
·
18
PDF
Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
2019
·
Shouzheng Wang
, Puyuan Xing
, et al.
·
Thoracic Cancer
·
17
PDF
Real world study of regimen containing bevacizumab as first‐line therapy in Chinese patients with advanced non‐small cell lung cancer
2018
·
Puyuan Xing
, Yuxin Mu
, et al.
·
Thoracic Cancer
·
17
Safety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with non-small cell lung cancer (NSCLC) treated on ATLAS
2008
·
J. Polikoff
, J. D. Hainsworth
, et al.
·
Journal of Clinical Oncology
·
15
Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
2020
·
Qing Li
, Jiani Wang
, et al.
·
Chinese Journal of Cancer Research
·
14
First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors
2024
·
Jian Zhang
, Yiqun Du
, et al.
·
npj Precision Oncology
·
12
PDF
The RRP9-JUN axis promotes breast cancer progression via the AKT signalling pathway
2024
·
Jinliang Huan
, Xiaojun Liu
, et al.
·
Biology Direct
·
9
PDF
A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors
2025
·
Jian Zhang
, Xiaojun Liu
, et al.
·
BMC Cancer
·
7
PDF
A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk.
2019
·
Jiani Wang
, Qing Li
, et al.
·
Journal of Clinical Oncology
·
7
The clinical significance of RET gene fusion among Chinese patients with lung cancer
2020
·
Puyuan Xing
, Nong Yang
, et al.
·
Translational Cancer Research
·
6
PDF
Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
2023
·
Yuxin Mu
, Yanchun Meng
, et al.
·
Thoracic Cancer
·
5
PDF
Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen
2020
·
Xuezhi Hao
, Yixiang Zhu
, et al.
·
Journal of Cancer
·
5
PDF
Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma
2018
·
Yixiang Zhu
, Puyuan Xing
, et al.
·
Thoracic Cancer
·
5
Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer
2018
·
Puyuan Xing
, Yuxin Mu
, et al.
·
Thoracic Cancer
·
4
PDF
Results and exploratory biomarker analyses of a phase II study CHANGEABLE: Combination of HX008 and niraparib in germ-line-mutated metastatic breast cancer.
2024
·
Yizi Jin
, Yiqun Du
, et al.
·
Journal of Clinical Oncology
·
2
Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting
2025
·
Jian Zhang
, Yuxin Mu
, et al.
·
Frontiers in Oncology
·
1
PDF
Phase I summary of the HB0025 efficacy and safety to the heavily pretreated non-small cell lung cancer (NSCLC) population.
2024
·
Yanchun Meng
, Yiqun Du
, et al.
·
Journal of Clinical Oncology
·
1
Show more works
View as search
Works count:
42
Citation count:
438
H-index:
13
I10-index:
14
Year
Topic
Type